Regulatory Reform To Boost U.S. Innovation And National Security [Forbes]
Precigen, Inc. (PGEN)
Last precigen, inc. earnings: 3/2 04:05 pm
Check Earnings Report
Company Research
Source: Forbes
As the former President and Chief Operating Officer of Intrexon, a biotechnology company focused on health, energy, food, and the environment, I have personal experience with the challenges faced by the private sector. AquaBounty and Oxitec are two companies that faced an exhausting experience in achieving regulatory approval for their groundbreaking products. While the federal government is making progress and appropriate risks must be managed, these challenges demonstrate how outdated regulatory systems continue to threaten innovation and competitiveness. Biotech Reform Case Study: AquaBounty AquaBounty developed the AquAdvantage Salmon, the first genetically engineered fish approved for human consumption by the Food and Drug Administration (FDA). The fish was engineered to grow in half the time of a wild Atlantic salmon and with one-third of the food. The AquAdvantage Salmon was a significant innovation, and the United States biotechnology community led the world in its develop
Show less
Read more
Impact Snapshot
Event Time:
PGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PGEN alerts
High impacting Precigen, Inc. news events
Weekly update
A roundup of the hottest topics
PGEN
News
- Precigen, Inc. (NASDAQ:PGEN) is definitely on the radar of institutional investors who own 31% of the company [Yahoo! Finance]Yahoo! Finance
- Precigen Is Still A Buy After The Papzimeos Rally [Seeking Alpha]Seeking Alpha
- Vaxart, Precigen among biotech gainers after Q3 results [Seeking Alpha]Seeking Alpha
- Precigen (NASDAQ:PGEN) had its price target raised by analysts at HC Wainwright from $8.50 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... [Yahoo! Finance]Yahoo! Finance
PGEN
Earnings
- 11/13/25 - Miss
PGEN
Sec Filings
- 12/22/25 - Form 4
- 12/22/25 - Form 144
- 12/16/25 - Form 4
- PGEN's page on the SEC website